Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hitting new 2+ year highs today on heavy volume, probably time to start watching this stock.
NGNM Zacks Report...http://www.zacks.com/ZER/zer_get_pdf.php?r=ZR_Z843295
I like this.company. I will be accumulating here.
There is lots of money to be made in diagnostics. Cancer testing has been reported to the highest growth area.
This CFA thinks this stock is an easy double in twelve months. I've been following the affiliate HDVY for a while and trust NGNM is off to its parabolic earnings growth stage.
When Wall Street misses small companies that are soon to be well recognized that's the time to pounce!
http://seekingalpha.com/article/390981-plenty-more-upside-in-neogenomics-shares
Gov't Grants of $374,000 (surprise, surprise)
NGNM to receive almost $0.4 million in government grants this month for the work its doing on new cancer diagnostics tests...what a pleasant surprise!!
I give credit to management for even submitting the applications, and glad to see them thinking outside the box a little bit. The $0.4 million will definitely help the company's cash flows this quarter.
NGNM – Solid Third Quarter Results
NGNM just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year, and an increase from the 15-18% expected revenue growth in 2010.
Clearly, the business has bottomed and the business model has reached critical mass.
NGNM at $1.10 is way undervalued and a great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.
NGNM – Strong Buy at $1
I like NGNM right here at a $1 per share. They've got a great management team, growing revenues, new cancer tests coming to market, great access to IP through their partnership with ABT and the infrastructure is already build and ready to handle a bigger business.
NGNM is going to be a big winner.
NeoGenomics Announces Anticipated Restructuring Charges for Q4 2009
http://finance.yahoo.com/news/NeoGenomics-Announces-prnews-1640923611.html?x=0&.v=1
.........looks like dead money for now.I guess they all misfire so I'll take it as a minor setback.Time will tell......
Press Release Source: NeoGenomics, Inc. On Thursday January 7, 2010, 10:09 am EST
FT. MYERS, Fla., Jan. 7 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it intends to take up to $500,000 in certain restructuring and other charges in the fiscal quarter ending December 31, 2009. These charges will cover costs in connection with restructuring the company's management team, including various severance obligations and recent recruiting fees. In addition, the Company is in the process of restructuring its relationship with Response Genetics, which provides NeoGenomics with KRAS-based molecular testing, which was unprofitable for the Company in 2009.
NeoGenomics also said the restructuring of the relationship with its largest client continued to have a significant impact. As a result, the Company will recognize approximately $1,100,000 less fluorescence in-situ hybridization (FISH) testing revenue from this client in the fourth quarter 2009 than it did in the fourth quarter 2008. This lost revenue had approximately 70% gross margins and thus far has only been replaced with approximately $300,000 of significantly lower margin immunohistochemistry testing revenue from this client.
Douglas VanOort, the Company's Chairman and CEO, stated, "Although we are still finalizing our year-end financials, we are currently expecting fourth quarter revenue in the range of $7.7 - $7.9 million and a net loss of approximately $1.3 - $1.5 million as a result of all of the above factors. While our sales force productivity continues to increase each month, it is not yet at an acceptable level. In addition, laboratory staffing has been increased in expectation of higher test volumes and for the launch of new products, and will result in a temporary reduction in gross margin. We currently expect fourth quarter 2009 gross margin to be approximately 47 - 48% of revenue."
"We are making significant organizational changes and expect to realize improvements in productivity. In addition, normal seasonal volume increases in the first quarter will add to our positive sales momentum and are expected to improve profitability. However, we continue to invest heavily in our new melanoma FISH test, which we expect to launch in late January. Investors should expect a net loss of approximately ($0.01)/share in the first quarter of 2010, but we believe that we can achieve break-even in the second quarter and return to profitability in the second half of 2010."
VanOort concluded, "We have nearly finished validating the new melanoma test and, thus far, the results are as we expected. We believe this new, one-of-a-kind FISH test will be very useful in helping to diagnose certain ambiguous and "grey zone" melanoma cases. Based on our market analysis and partner feedback, there appears to be considerable interest in this new test from the pathology community. Although we expect revenue from the melanoma test to start off modestly, we believe it will provide additional momentum for our business as 2010 unfolds."
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.
AWFULLY QUIET FOR A STOCK THAT JUST BROKE THE HIGHEST RESISTANCE FOR THE LAST 3 YEARS LOL LOL
I will work on Ibox tonite..
Maybe this is my next DDRX, I found that under $1 in March and it's now almost at $25...
Will do some DD here but future revenues off this deal could value this north of $10 maybe close to $20.
$500 million cap = $15 PPS..
NeoGenomics to Present at Noble Financial's 5th Annual Equity Conference on Monday, June 8th
Jun 5, 2009 10:11:00 AM
Email Story Discuss on ZenoBank
View Additional ProfilesFT. MYERS, Fla., June 5 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM) today announced that it will present at the Fifth Annual Noble Financial Equity Conference at 9:15 AM EDT on Monday, June 8, 2009 at the Seminole Hard Rock Hotel in Hollywood, FL. Robert Gasparini, the Company's President and Chief Scientific Officer will give a presentation regarding NeoGenomics' market positioning, financial performance, and strategic direction and then answer questions from the audience. The presentation will be webcast LIVE featuring high-definition, streaming video and PowerPoint slides. Access is available by logging on to http://hosted.mediasite.com/mediasite/Viewer/?peid=a11b62efcbec4c8f90dfa8f3ca8d3cd8. In addition, a portal to the webcast will be available in the Investor Relations section of the NeoGenomics' website at http://www.neogenomics.org/investor.asp. It is recommended that interested parties register at least 10 minutes prior to the start of the presentation to ensure timely access to the webcast.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.
About Noble Financial
Noble Financial is a privately-held, full-service capital markets firm driven by what is often overlooked by other firms - uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting market inefficiencies into profit opportunities. Noble Financial supports emerging companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble Financial's equity conferences - 2009 marks their fifth annual - allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The company has operated for 25 years and has offices in Florida, New York City and Boston.
SOURCE NeoGenomics, Inc.
----------------------------------------------
Steven C. Jones
Director of Investor Relations
NeoGenomics
Inc.
+1-239-325-2001
sjones@neogenomics.org; or Ms. Julie Marshall
Hawk Associates
Inc.
+1-305-451-1888
neogenomics@hawkassociates.com; or The Investor Relations Group: Investor Relations: Rachel Colgate
+1-212-825-3210
rcolgate@investorrelationsgroup.com; or Media Relations: Janet Vasquez
+1-212-825-3210
jvasquez@investorrelationsgroup.com
AMI Research Provides Q1 2009 Stock Valuation Report on NeoGenomics, Inc.
May 8, 2009 9:30:00 AM
Email Story Discuss on ZenoBank
View Additional ProfilesKEY LARGO, FL -- (MARKET WIRE) -- 05/08/09 -- AMI Research, a division of Hawk Associates, today announced that it has updated its stock valuation report of NeoGenomics, Inc. (OTCBB: NGNM) based on the company's first quarter results. The complete 16-page report is available as a free download at the AMI Research website, http://www.amistockreports.com.
NeoGenomics specializes in cancer genetics, flow cytometry and molecular diagnostic testing. The company's laboratories offer superior service, industry leading turnaround times and complete dedication to its clients and patients. Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, CA and Fort Myers and provides diagnostic tests to pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, please visit http://www.neogenomics.org.
About AMI Research
AMI Research is a leading provider of issuer-paid stock research coverage and a division of Hawk Associates Inc. AMI Research offers high quality and credible fundamental analysis of promising small companies that do not have traditional Wall Street analyst coverage. Please visit http://www.amistockreports.com.
AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst's compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.
For more information, contact Frank Hawkins or Julie Marshall at 305-451-1888, email to: director@amistockreports.com or visit http://www.amistockreports.com.
Add to Digg Bookmark with del.icio.us Add to Newsvine
AMI Research
Phone: (305) 451-1888
E-mail: Email Contact
http://www.amistockreports.com
YAHOO MESSAGE BOARD NOW THE MOST ACTIVE NGNM BOARD
http://messages.finance.yahoo.com/mb/NGNM.OB
NeoGenomics, Inc. Announces the Licensure of its California Laboratory Location and Schedules its Q4 06 Earnings Conference Call
Ft. Myers, Florida – February 27, 2007 – NeoGenomics, Inc. (NASD OTC BB: NGNM) announced today that it has received a laboratory license for its new Irvine, California laboratory location and has received certification for this laboratory under the Clinical Laboratory Improvement Act, as amended (CLIA) through inspection by the California Department of Health.
NeoGenomics President, Robert Gasparini, said, “I am delighted to report that as a result of obtaining our license, we can now commence revenue operations at this facility. Revenues will start out modest as we continue to hire staff for this location, but, over time, we believe that California and the surrounding markets will be substantial contributors to our revenue and earnings growth. As cancer is primarily a disease of the elderly, the cancer genetics industry tends to do very well in areas where there are high concentrations of senior citizens. Indeed, the marketplace in southern California is similar in many respects to the marketplace in southern Florida, where NeoGenomics already has a substantial presence. We are excited to bring our industry-leading turn-around-times to the oncologists, urologists, pathologists and hospitals in this market and are hopeful that our services will be as warmly received in California as they have been in all of our other locations.”
In other news, NeoGenomics also announced that it would release its final Q4 FY 2006 and full year earnings on Wednesday, March 14, 2007. The Company has also scheduled a web-cast and conference call to discuss these results on March 14th, at 11:00 AM EST to discuss these results. Interested investors should dial (877) 407-0778 (domestic) and (201) 689-8565 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on March 28, 2007 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback account number is 286 and the playback conference ID#/PIN# is 233199. The web-cast may be accessed under the Investor Relations section of the NeoGenomics website at http://www.neogenomics.org or at the website of our Investor Relations firm, Hawk Associates, at http://www.hawkassociates.com/ngnmmore.aspx or at http://www.vcall.com/IC/CEPage.asp?ID=114420. An archive of the web-cast will be available until 11:59 PM EST on June 11, 2007.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
Interested parties can also access additional investor relations material, including an in-depth equity research report, from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com. An investment profile about NeoGenomics may be found at http://www.hawkassociates.com/ngnmprofile.aspx.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
American Microcap Institute Maintains 'Strong Buy' on NeoGenomics
Cancer Genetic Testing Lab Raises FY '07 Guidance, Announces Growth Initiatives
KEY LARGO, Fla., Jan. 19 /PRNewswire/ -- The American Microcap Institute (AMI), a leading online resource for microcap investors and a division of Hawk Associates Inc., announced today that it issued an update to its analyst coverage on NeoGenomics, Inc. (OTC Bulletin Board: NGNM) based on the company's third quarter earnings.
NeoGenomics is an independent medical laboratory company specializing in genetic testing for cancer. AMI maintained its 'strong buy' rating and set a price target range of $1.80 to $2.10 by the end of 2007. The third quarter of 2006 was NeoGenomics' third consecutive profitable quarter. Total revenues grew 186% year-over-year but decreased 9% on a sequential basis due to seasonality and a transition in customer base to higher margin clients. The company also announced a record number of new customers in Q3, the opening of a new lab in Irvine, Calif., and the introduction of a new genetic pathology solutions (GPS) testing service. Subsequent to the release of Q3 earnings, NeoGenomics also announced the launch of the industry's first tech-only FISH testing service for pathologists.
The third quarter analyst update and previous reports on the company can be accessed for free on the AMI Research website, http://www.amistockreports.com.
About AMI Research
AMI Research, a service of the American Microcap Institute, provides fundamental research on promising small companies that do not have traditional Wall Street analyst coverage. These detailed issuer-paid research reports provide investors with an in-depth understanding of a company and its technology, industry, business model, financials and growth prospects.
AMI Research does not accept payment of fees in company stock. Principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in AMI reports accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by the company is in any way related to the specific ratings or views contained in the report. Please read all disclosures and certifications in each report prior to investing. For more information, visit http://www.amistockreports.com.
About The American Microcap Institute (AMI)
The American Microcap Institute (AMI) is a leading online resource for microcap investors and a division of Hawk Associates Inc. AMI is dedicated to providing investors with timely and accurate information on companies trading under $10. The AMI website provides investors with a free stock watch list and information about featured microcaps, company headlines, 20-minute delayed Level II price quotes, email alerts, CEO interviews and research reports. No registration is required to access the site. For more information, visit http://www.americanmicrocaps.com.
About Hawk Associates Inc.
Hawk Associates, Inc. is a full-service national investor relations and financial media relations consulting firm serving clients nationwide as well as in China and Vietnam. Hawk Associates operates the American Microcap Institute website, http://www.americanmicrocaps.com. For more information about Hawk Associates, visit http://www.hawkassociates.com or contact Frank Hawkins or Julie Marshall at (305) 451-1888, e-mail: info@hawkassociates.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, Fla., and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
An investment profile about NeoGenomics may be found online at http://www.hawkassociates.com/ngnmprofile.aspx. Interested parties can also access in-depth equity research from the American Microcap Institute at http://www.americanmicrocaps.com/ngnm.
An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com. For investor relations questions regarding NeoGenomics, contact Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 451-1888, e-mail: info@hawkassociates.com.
SOURCE Hawk Associates Inc.
Source: PR Newswire (January 19, 2007 - 9:20 AM EST)
News by QuoteMedia
www.quotemedia.com
I just noticed I meant to say cup and handle not saucer, must not have gotten enough coffee yesterday morning.
I am new to the board and really like the propects of NGNM. The average P/S of my position is 1.35 and look forward to seeing it rise. I think we see 2.00 mark this run. With the guidance being adj for yearend not sure how this will affect the stock price but if the conference call does not result in disappointment or much apprehension as to the effects of the customer mix changes we may see a slight correction (back down to 1.75) after hitting the 2.00 - 2.10 point followed by a large run to the 3.00 - 3.50 range. If sales/expansion goes as planned we might see 4.00 - 4.50 by the end of next year. According to technical analytics I think we are on the backend of "cup & saucer" pattern which is a classic continuation pattern. Lovin the new human capital additions. I am really impressed by gasparini's confidence in the business model.
cool!--
maybe we head north of 2 this run..........
Yahoo NGNM Message board now open...
http://messages.finance.yahoo.com/mb/NGNM.OB
there was a single 270K print that sent the day's volume total into the 400's...not sure if it was a buy or a sell...overall I'm seeing general accumulation in the chart.
What is with the price movement today. It was so nice to see; it has been so long around $1.45 to $1.50 per share.
Is it all due to speculation regarding 4Q06 earnings being released soon? Not sure if 4Q earnings will be as great as was expected relating to the last PR with the rollout of the new technology; but, LONGTERM...WOW!!
Any thoughts...
INXS2121
Thanks Cash - I'll check it out.
I'm moving on to NGNM google message board.
I think with Neogenomics' increasing awareness the google board should become more active than this one. Whenever NGNM moves off the over-the-counter penny stock listings the Yahoo board should open up -but I dislike the yahoo boards- a person has to sort through too much crap to get to the intelligent posts.
Google message board for NGNM:
http://finance.google.com/group/google.finance.12209185/messages
I was thinking maybe just a 10 to 15% drop on the announcement of the share dilution. I don't think it would fall below the 50 day line (currently it's at $1.27). Institutional investors are entering the stock and they tend to support the price by not letting it fall below the 50 day average line. They will prop it up anytime it starts approaching it. That is a common trait of stock that has institutional support. You can see it in NGNM's chart this year. http://stockcharts.com/gallery/?NGNM So a warning sign would be if the price plummeted through that line on high volume -meaning the institutional investors were exiting the stock and no longer supporting it.
Based on Gasparini's track record and the area that this company does business in...I could see the stock doubling to $4 next year then doubling again to $8 and so on...but when we enter a bear market or a correction -all those gains will be put on hold or even given back. If NGNM starts to fall in sync with the market then it will probably be a good time to take profits and sit on the sidelines till the correction is over (3 out of 4 stocks follow the market's general direction) BUT if NGNM were to hold its stock price or only fall a little bit that would mean it is a very strong stock and should be held since it would then skyrocket out of the gate when the next bull market started.
Cash how low do you think the S/P will go? Under $1 again? That would be an outstanding time to buy in again but I don't think it will go there. I do think this stock has the capability to hit the $100 mark if their business model and market demand stays on track and I don't see any reason for it not to. Your thoughts?
Pullbacks on declining volume is what I like to see...just like the last two days.
At the JPM conference, management said they would be raising additional funds in 1H07...$2 to 3M...which could go for paying off the $1.5M debt. That will bring more dilution to the share count and a sell off on the announcement but that will be a good time to add shares as I expect the share price to quickly recover. This rocket ride will then be debt free and even more attractive to investors. I would think the JPM investors wouldn't want to wait till next year to buy in so maybe we will see that financing happening sooner than planned and for a larger amount.
I was looking at the long term chart for PTRY -a convenience store chain. It went from $1 to $70 in 4 years. I wonder if this stock could do the same? Especially now that they announced they will be doing research and development and will be looking to introduce intellectual property into their business model.
Excellent Rapid-Rapid pace presentation!
I think Robert took only two breaths during the first 15 minutes! Lots of specific details about the business and future potential. This is definitely a rocket ride!
Hit a high of $2.05 today! And it continually keeps rising on -heavy- above average volume. A warning sign would be if it were to be hitting new highs on below average volume. That ain't happening here.
http://www.mapdigital.com/jpmorgan/smallcapboston06/
once you register, they are under on-demand web casts. Lots of important information for NGNM investors...
Another strategy note from IBD:
Pullbacks To 10-Week Line Offer 2nd Chance
Some stocks give you a second chance.
Maybe you were slow in pulling the trigger and missed buying into a stock as it broke out of its base. Or perhaps you were quick enough to snatch up some shares, but want to add to your holdings.
Winning stocks will periodically take a break during their run and drift back to their 10-week or 50-day moving averages. A stock that bounces off these key benchmarks is said to be finding institutional support. That means big investors are stepping in to buy shares and, by boosting demand, lifting the price.
The easiest way to determine when to buy shares is to look at a weekly stock chart. Mini charts in Investor's Business Daily and weekly charts at investors.com show the 10-week and 40-week average lines.
When a growth stock that's been heading higher falls back to touch its 10-week or 50-day line, then begins to climb higher, it's time to start scouting out a buy point.
The buy point is 0.10 above the highest price the stock hit before it began to pull back.
Ideally, you like to see volume pick up as a stock ricochets off its moving average line - the bigger the volume, the more institutional support it's attracting.
On the flip side, a stock that falls through its 10-week moving average on heavy volume and continues south may be in trouble. If you own it, you might consider selling, especially if the stock cannot rally back.
OT: I sure like the spell checker that google has on their free web browser toolbar...comes in real handy for spell checking these comments before posting here and on the yahoo boards.
http://toolbar.google.com/T4/index_xp.html?utm_source=en-et-more&utm_medium=et&utm_campaign=...
Keep in mind that the main purpose of a companies attendance at these conferences, such as the JP Morgan Small Cap Conference, is to raise additional funding and investment. Usually a PR will follow these events announcing the sale of more shares...the stock will fall on that news but it can be a good time to add shares since the price will typically recover in a month or two. Neogenomics is going to need additional cash to fund the new lab in Southern California. I also expect them to acquire additional companies in other areas of the country, since as they said they are in acquisition mode.
NeoGenomics enjoys $1.6M revenue growth
NeoGenomics has added employees, tripling its staff in Nashville and doubling the size of its sales team.
By Laura Layden
Saturday, November 11, 2006
It's all in the genes.
Fort Myers-based NeoGenomics Inc. is growing along with its industry.
The genetic testing company saw revenues climb to more than $1.6 million in the third quarter, a 186 percent increase from the same quarter a year ago.
Profits grew by $271,800 to $32,000, from a loss of $239,900 a year ago.
"This was quite the exciting quarter for us here at NeoGenomics," said Robert Gasparini, the company's president and chief scientific officer, in a conference call Friday.
He said the most significant accomplishment during the quarter was the development of physical and human resources needed to "begin to scale" the company. NeoGenomics has completed an expansion of its Fort Myers headquarters and the build-out of a new 5,400-square-foot laboratory in Nashville, Tenn.
In July, NeoGenomics opened a new laboratory in California, giving it a "bicoastal presence," company officials said.
At the same time, the company has added employees, tripling its staff in Nashville and doubling the size of its sales team.
New hires include Matthew Moore, who has a doctorate in molecular biology and is expected to expand the company's intellectual property and its reach to pharmaceutical research and development organizations. In the past, the company has primarily performed diagnostic testing for patients, not for research.
Also joining NeoGenomics as associate medical director is Frank Yang, a noted hematopathologist.
Steven Jones, acting principle financial officer, said the company's accomplishments in the third quarter are a testament to the strength of its business model.
In the quarter, the company saw a 160 percent increase in the number of tests performed, and a 10 percent increase in the average revenue per test.
Year-over-year the company's profits are up 242 percent. Revenues are up 316 percent.
Based on the growth NeoGenomics has seen so far this year, company officials on Friday raised guidance for 2007. Revenues are now pegged at $14 million to $16 million and profits are estimated at $1.3 million to $1.7 million. The new estimates are based on internal growth, not on acquisitions or new strategic alliances.
The company has been asked to make a presentation to investors at the JP Morgan Small Cap Conference on Wednesday at the Four Seasons Hotel in Boston. Company officials said it was a great honor to be invited. In the past, the company has attracted individual and high net worth investors. Now institutional investors are taking notice.
"We're excited to begin to tell our story," Jones said.
The company reached the milestone of monthly profitability in February. It provides testing services to oncologists, pathologists, urologists, hospitals, and other laboratories. It specializes in genetic testing for cancer.
The company trades under the symbol NGNM on the Over-the-Counter Bulletin Board. Shares closed at $1.59, down 9 cents, on Friday.
© 2006 Naples Daily News and NDN Productions. Published in Naples, Florida, USA by the E.W. Scripps Co.
http://www.naplesnews.com/news/2006/nov/11/neogenomics_enjoys_16m_revenue_growth/?print=1
IBD's investor's corner has this lesson and advice this weekend.
Don't Fall In Love With A Stock — Use Sell Rules To Guide Your Hand
http://www.investors.com/editorial/editorialcontent.asp?secid=1100&status=article&id=2480521...
I check investor's corner everyday -good examples of what to watch out for.
Exciting conference call...lots of good news...being invited to the JP Morgan Small Cap Conference next Wednesday is impressive -Neogenomics will be the smallest cap stock there...obviously, wall street sees the potential of this company. I expect some large institutional investors to enter the stock after next week's conference. They aren't going to pay top price for their shares, though -expect more shakeouts.
Once a stock reaches or goes above the upper bollinger band you can expect a quick trip downward. Plus, like I pointed out it was too high above the 50 day line and ready for a reversal. Or, I wonder if the MM's just wanted to scare and grab the shares of all those who follow those penny stock sheets and took a position on Wed?
Not sure what's next for the stock -depends on what is said tomorrow.
As for the future...people are going to start taking their Q4 profits next month. And I see that large cap stocks are gaining favor which usually happens at the end of a bull market...so we could be heading into a correction or bear market next year which will pull down on this stock...for now, gotta just keeping watching out for warning and sell signs. Today (Thursday) looked like one but the stock ended up reversing and finishing in the upper half of the candlestick -a bullish sign!
see chart: http://stockcharts.com/gallery/?NGNM
When do we get back in?
Big selling during lunch after everybody seen what happened this morning? Do you want to be holding over the weekend?
Is the market pulling NGNM down?
It seem that NGNM follows the market. Big gains in the market this week. Monday might be a good time to get back in.
cashprofitsss - "The price is getting way to high above the 50 day line"
The news services will bring in the volume and the price will get volitile. The price will move fast, both ways, with the big volume.
What I do is try not fall in love with a stock. Get in and get out. Take your profit. You can beat yourself up because you didn't sell closer to the top than what you think you should have. This is very hard to do. I find myself falling in love with stocks. If we could find a stock to hold long, it would be easy.
NGNM is making money and doing very good things. There should be some good buying opps after the big sell off.
I checked the news services and I see OTCpicks.com, twintraders.com, wallstreetnewsalert.com, stockwire.com -all putting alerts out to their penny investors on NGNM. So much for thinking no one knew about this stock -yet. (That's where the volume is coming from.) I'd rather not see these type of companies pumping NGNM. I want to see long term investors in Neogenomics -not penney investors who sell every time the stock goes up 3 cents. Unfortunately, the stock will become very volatile now.
The price is getting way to high above the 50 day line -going to be time for a reversal. Also, keep an eye out for "churning" on Friday. That's when there is extremely heavy volume but the stock price doesn't rise much -too many people selling into the news.
http://stockcharts.com/gallery/?NGNM
Here's where the volume came from today....
I profiled NGNM to my subscribers at www.insightertrading.com last night. Google "insightertrading.com" and you'll see some other quality growth stories we've been in. Just thought you fellow NGNM longs might want to point out any oversights in my analysis of the firm.
~~PASTE OF NGNM PROFILE @ $1.75~~
[11/8/2006] NGNM - Molecular diagnostics under the microscope...
01:43:43am
2006-11-08
The medical diagnostics business it a pretty boring industry. Certainly it lacks the compelling stories like clinical trials, big pharma buyouts, and FDA approvals. However, there is a segment of the industry that's on fire right now.
The industry as a whole can be drilled down to three segments:
Clinical Testing - This is what we're all familiar with. Low margins, and high volumes of simple blood and urine tests. These tests generate about $5-$30 in revenue per test and this segment is growing in the low single digits.
Anatomic Pathology - Many of us have had experience with this segment via Pap smears, skin biopsies, and tissue biopsies. These tests generate between $25 and $500 per test and the growth here is about 7% annually.
Genetic/Molecular Testing - This is the space that NGNM (Neogenomics) operates in. This segment involves analyzing chromosomes, genes or base pairs of DNA for disorders. Both genetic and molecular testing have become important and highly-accurate diagnostic tools over the last five years. New tests are being developed rapidly, thus this market segment is expanding rapidly. Genetic/molecular testing requires very specialized equipment and credentialed individuals (typically MD or PhD level) to certify the results and typically yields the highest average revenue per test of the three market segments. The tests NGNM performs for example yield between $200-$1,000 per test. In fact, in the first half of '06, NGNM's average revenue per test was $706.
So now that we know where NGNM is located in the spectrum of medical diagnostics, let's look for some evidence of the growth in this space. Before we look at NGNM's results, let's look at some of their competitors.
MYGN - Trading at $28.56 it's just pennies off of a new 52 week high. This $1billion market cap firm just smashed estimates and here's what they had to say about the molecular diagnostic market....
~~PASTE~~
43% Revenue Growth and 95% Operating Income Growth Highlight Molecular Diagnostic Business -
For the three-month period ended September 30, 2006, molecular diagnostic revenue increased to $30.9 million from $21.5 million in the same quarter of the prior year, an increase of 43%.
"We are very pleased with the continued growth in our molecular diagnostic business and the advances in moving our drug candidates towards the market," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We believe that the remarkable growth in top-line revenues and the substantial improvement in operating profits are indicative of a vigorous, growing molecular diagnostic business."
~~END PASTE~~
Now let's take a look at what NGNM has recently said about it's markets...read closely....
~~PASTE~~
We have an opportunity to add additional types of tests to our product offering. We believe that by doing so we may be able to capture increases in our testing volumes through our existing customer base as well as more easily attract new customers via the ability to bundle our testing services more appropriately to the needs of the market. Until December 2004, we only performed one type of test, cytogenetics, in-house, which resulted in only one test being performed per customer requisition for most of FY 2004 and average revenue per requisition of approximately $490 in FY 2004. In December 2004, we added FISH testing to our product offering, and in February 2005, we began offering flow cytometry testing services. With the addition of these two new testing platforms, our average revenue/requisition increased by 35.6% in FY 2005 to approximately $632/requisition.
We believe this bundled offering approach could drive large increases in our revenue and afford us significant synergies and efficiencies in our operations and sales and marketing activities. For instance, initial testing for most hematological cancers may yield total revenue ranging from approximately $1,700 - $2,800/case and is generally comprised of one or more of the following tests: cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, and morphology testing. Whereas in FY 2004, we only addressed approximately $500 of this potential revenue per case, we now address approximately $1,200 - $1,900 of this potential revenue per case.
~~END PASTE~~
So how is this "bundled" approach working for NGNM? Take a look at their last Quarterly....
~~PASTE~~
For the three months ended June 30, 2006 our revenues increased 413% to approximately $1,767,500 from approximately $344,900 in 2005. This was the result of a 353% increase in testing volume and a 13% increase in average revenue per test. For the six months ended June 30, 2006 our revenues increased 441% to approximately $3,111,300 from approximately $575,100 in 2005. This was the result of an increase in testing volume of 397% and a 9% increase in revenue per test. This volume increase is the result of wide acceptance of our bundled testing product offering and our industry leading turnaround times resulting in new customers. This increase in revenue per test is a direct result of restructuring arrangements with lower revenue per test and pricing policies with new customers.
~~END PASTE~~
Nice margins on this business too, and those margins will continue to ramp as revenue per test scales higher....
~~PASTE~~
As a result of the revenue and cost of revenue our gross profit percentage for the three months ended June 30, 2006 increased to 59% from 47% for the three months ended June 30, 2005. The gross profit percentage for the six months ended June 30, 2006 increased to approximately 58% from approximately 40% for the six months ended June 30, 2005.
~~END PASTE~~
And they just swung to profitablity to boot....
~~PASTE~~
As a result of the foregoing, our net income for the three months-ended June 30, 2006 increased approximately $342,600 to approximately $161,300 from a loss of approximately $181,400 during the three months-ended June 30, 2005. For the six months-ended June 30, 2006 net income increased approximately $664,200 to approximately $267,700 from a loss of approximately $396,500 during the six months-ended June 30, 2005.
~~END PASTE~~
Looks like a nice little growth story here for a company with a $40million dollar market cap, and about 10million shares in the float. Yes, 9 times sales is expensive, but it's mitigated if you factor in the 400% revenue growth year over year.
There's also this little nugget that was buried in the last paragraph of a press release from September when the firm announced their new bundled tests aimed at the oncology market dubbed "GPS"....
~~PASTE~~
"Overall, we are excited about the impact that we believe the GPS product will have on our growth rate in FY 2007. As we announced with our Q2 06 earnings release we plan to issue revised upward guidance for FY 2007 with our Q3 06 earnings release."
~~END PASTE~~
Never underestimate how surprised the market can be by information that a company has previously disclosed. It happens all the time. Now the stock has been trading higher into it's earnings call on Friday. The shares printed a fresh high today of $1.78 so it appears as if there is some money out there that remembers the revised guidance comment I pasted above.
Decent support at $1.40 and very firm support at $1.15.....
Related Industries: Health - New Pick - Overlooked Potential - Pharmaceutical -
Initial Stock Price: $1.75
NeoGenomics Announces Third Quarter Earnings and Conference Call
I like that they are doing this before the bell and the price can run up all day Friday.
NeoGenomics Announces Third Quarter Earnings and Conference Call
FT. MYERS, Fla., Nov. 7 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) will release its third quarter earnings on Friday, Nov. 10 at 7 a.m.
NeoGenomics will hold a conference call with President and Chief Scientific Officer Robert Gasparini and key members of the management team the same day at 10 a.m. Eastern Time. The call will cover the company's third quarter results and will include a question-and-answer session.
To participate, call (877) 407-8035 any time after 9:50 a.m. Eastern Time on Nov. 10. International and local callers should dial (201) 689-8035. While in conference, if callers should experience any difficulty or require operator assistance, they can press the (*) followed by the (0) button. This will call an operator to the line.
A live webcast of the call will be available at http://www.vcall.com/IC/CEPage.asp?ID=110964 and will be accessible until March 2, 2007. Viewers will need Windows Media Player or Real Player to listen to the broadcast. To download Media Player, go to http://www.microsoft.com/windows/windowsmedia/download.
http://biz.yahoo.com/prnews/061107/clw062.html?.v=68&printer=1
Cashprofitsss...
Nice update on recent activity.
It is amazing to think that i am in this company at a cost of $0.38 per share. I am getting a little concerned about a natural selloff; but i don't want to lose out on further upside as I think this is a $4 or $5 stock over the next 2 years.
I too believe that news if forthcoming; and with the expectation of the market; the news has got to be GREAT.
This is all JMHO!!
INXS2121
Big trade @ $1.70
Good info Cashprofitsss. G & J are doing good for us investors. It took a while to get over $1.50. With the volume and big trades picking up, $1.75 might be easier, with some selling. $2 will be very difficult. I think the volume is going to drive NGNM. When we hit 1 mil/day, price will move fast and we could go over $2 easy. 10 mil/day volume and we see straight up and then straight down.
note on monday's activity:
NGNM: Volume Spike; 99% > 20-adsv, Stock +9.33%
Monday , November 06, 2006 16:10ET
This is the 1st VOLUME alert for NGNM in the past 7 calendar days.
Trading for NeoGenomics Inc (OTCBB: NGNM) has been heavier than usual in today's session. By 16:10 ET, the stock had already traded 283,600 shares via 43 trades. The cumulative volume is 98.90% above its 20-day average of 142,582. Normally the stock experiences around 23 individual trades per session.
So far, today's volume surge has caused a net rise in NGNM's stock price. At the time of this alert, the stock was trading at $1.640, up $0.140 (+9.33%).
One year ago, the Company's shares closed at $0.240. The price has gained more than 583 percent since then.
Over the last 10 trading session NGNM has traded in a range between $1.150 and $1.540 and is currently trading 6.49% above its 52-week high of $1.540 set on November 01,2006 and 1266.67% above its 52-week low of $0.120 from January 18,2006.
In the previous 3 sessions, NGNM trading has displayed a mixed trend. Closing results have been as follows:
November 03, 2006 --- closed at $1.500 up $0.040 (+2.74%) on 279,600 shares
November 02, 2006 --- closed at $1.460 down $0.040 (-2.67%) on 63,160 shares
November 01, 2006 --- closed at $1.500 up $0.080 (+5.63%) on 201,000 shares
The Company last released news on September 25, 2006:
"NeoGenomics Unveils Comprehensive Genetic Pathology Solutions (GPS) Product Offering"
NEOGENOMICS INC
NeoGenomics, Inc.'s principle operations include providing cytogenetic and molecular biology diagnostic testing services to the oncology and perinatology sectors of the healthcare industry. The Company also conducts research activities for the early diagnosis of women's diseases, such as ovarian cancer, as well as diseases in prenates and infants.
http://knobias.com/story.htm?eid=3.1.2160c501478e1b0ab77f6e9c9eb265fa6d63b1fdf3b434f7e0e91e0c3b3ea17....
Thanks for the info Cash. Things looking great so far.
From what I've read, Us Labs is a wholly owned subsidiary of LabCorp now. The parent company, Lab Corp, is LH stock symbol. Look down at the second -weekly chart- and you will see they have done quite well the last 3 years.
http://stockcharts.com/gallery/?lh
NGNM did around 400k today in volume...news is obviously about to hit!
rogerreuss, smart entry and exit on BCON -congrats! You knew that any stock that goes straight up like that -you'd better grab your profits before the sell off. I feel more comfortable this time about NGNM since its rise is happening over a longer period in stages/bases. One still has to watch out for warning/sell signs like a high volume plummet through the 50 day. At some point people will want to take their profit in this stock but I'm guessing it will be a gradual fall not abrupt. Few people know about NGNM yet and we are still in early in this rise yet. Most likely scenario for this company is they will be bought out by Quest Diagnostics (DGX) or Laboratory Corp (LH) at a 50% premium in a couple of years. But then again Gasparini & Jones might not want to sell their baby...
That's good insight on the upcoming $1.75 & $2.00 hurdles. Yes, it usually takes a couple of pull-backs before overtaking future resistance levels.
The rise this year was in part the result of Neogenomics hiring Hawk Associates to promote the stock and provide analyst coverage. NGNM is paying them almost 7K a month for these and investor relation services. I must say though that their analyst, Cale Smith, writes an excellent report and he is even critical at times. Keep in mind though at the moment we have a company that will only net about 500k this year and is 1.5M in debt. But based on Gasparini and his teams past performance and the high-margin market they are in and the 25 to 45% annual growth predicted...we should see a continued escalation of the stock price...just got to be careful that it doesn't get too far out of line but so far we have had high volume to support the rise.
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
303
|
Created
|
08/29/02
|
Type
|
Free
|
Moderators |
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
NeoGenomics offers the complete spectrum of diagnostic services in immunohistochemistry, FISH, flow cytometry, cytogenetics, and molecular testing through our nationwide network of laboratories. We are dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |